Jackowska 2003.

Methods	Unclear if this is a randomised controlled trial.
Participants	107 children (age nm; sex nm) with acute lymphoblastic leukaemia (stage nm) treated with either doxorubicin or daunorubicin containing therapy (cumulative dose 120 mg/m2; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction nm.
Interventions	Dexrazoxane (ratio to anthracycline nm; timing in relation to anthracycline nm) (N = 43) versus no cardioprotective intervention (N = 64).
Outcomes	Toxicities other than cardiotoxicity.
Notes	Unclear if this is an ongoing or completed study. Unclear if cardiotoxicity is evaluated in this study. Length of follow‐up nm. Cumulative anthracycline dose per treatment group nm. Age per treatment group nm.